Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates significantly due to a non-cash IPR&D impairment charge of $9.2M, leading to a GAAP EPS of -$0.34 vs. the -$0.14 expected. Revenue remained at zero, consistent with its development-stage status, while operating losses widened to -$14.1M. The company’s cash runway is critical, with $9.6M on hand expected to fund operations only into Q4 FY26, necessitating imminent financing.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Dogwood Therapeutics(DWTX) the EBIT is -4.873 M (-24.2%), Miss estimate;the EPS is -0.34 (+82.91%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.00B24.20%
-0.00B20.29%
-0.00B3.91%
EPSMiss expectations
-0.3482.91%
-0.136793.13%
-0.203310.22%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf